S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Anika Therapeutics Stock Forecast, Price & News

-0.12 (-0.30 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $39.83
50-Day Range
MA: $41.29
52-Week Range
Now: $39.83
Volume89,584 shs
Average Volume117,165 shs
Market Capitalization$566.18 million
P/E RatioN/A
Dividend YieldN/A
Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Therapeutics logo


Overall MarketRank

1.91 out of 5 stars

Medical Sector

82nd out of 1,928 stocks

Surgical & Medical Instruments Industry

13th out of 170 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:ANIK



Sales & Book Value

Annual Sales$114.51 million
Cash Flow$2.55 per share
Book Value$20.21 per share


Net Income$27.19 million


Market Cap$566.18 million
Next Earnings Date2/18/2021 (Estimated)
-0.12 (-0.30 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

How has Anika Therapeutics' stock price been impacted by COVID-19?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANIK shares have increased by 9.5% and is now trading at $39.83.
View which stocks have been most impacted by COVID-19

Is Anika Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Anika Therapeutics stock.
View analyst ratings for Anika Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Anika Therapeutics?

Wall Street analysts have given Anika Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anika Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Anika Therapeutics' CEO?

1,428 employees have rated Anika Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Anika Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Anika Therapeutics

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) released its quarterly earnings results on Monday, November, 9th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.44. The biotechnology company earned $31.69 million during the quarter, compared to analysts' expectations of $32.22 million. Anika Therapeutics had a negative net margin of 5.18% and a positive return on equity of 2.63%.
View Anika Therapeutics' earnings history

What price target have analysts set for ANIK?

2 brokerages have issued twelve-month price targets for Anika Therapeutics' shares. Their forecasts range from $43.00 to $61.00. On average, they expect Anika Therapeutics' share price to reach $52.00 in the next year. This suggests a possible upside of 30.6% from the stock's current price.
View analysts' price targets for Anika Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Dr. Cheryl R. Blanchard, Pres, CEO & Director (Age 57, Pay $62.5k)
  • Mr. Thomas M. Finnerty, Exec. VP of HR (Age 63, Pay $550.34k)
  • Mr. James Loerop, Exec. VP of Bus. Devel. & Strategic Planning (Age 57, Pay $549.09k)
  • Mr. Michael L. Levitz, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Alexei Goraltchouk, Sr. VP of Operations & Project Management
  • Kristen Galfetti, Exec. Director of Investor Relations
  • Mr. Charles Sherwood III, VP & Corp. Legal Counsel
  • Mr. David Colleran, Exec. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Mr. James Chase, Sr. VP of International Sales & Marketing
  • Mr. Bart Bracy, VP of Sales & Marketing of Americas

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (2.66%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, James Loerop, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung.
View institutional ownership trends for Anika Therapeutics

Which major investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Anika Therapeutics company stock in the last year include James Loerop, and Raymond J Land.
View insider buying and selling activity for Anika Therapeutics
or view top insider-selling stocks.

Which major investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp.
View insider buying and selling activity for Anika Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $39.83.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $566.18 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 154 workers across the globe.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.